Literature DB >> 26560024

Procalcitonin levels predict infectious complications and response to treatment in patients undergoing cytoreductive surgery for peritoneal malignancy.

K Saeed1, A P Dale2, E Leung3, T Cusack2, F Mohamed3, G Lockyer2, S Arnaudov3, A Wade4, B Moran3, G Lewis2, M Dryden5, T Cecil3, J A Cepeda6.   

Abstract

BACKGROUND: Cytoreductive-surgery for peritoneal-malignancy (PM) involves extensive intra-abdominal surgery and a massive post-operative systemic-inflammatory-response (SIRS). It is often challenging to differentiate SIRS that are solely surgery-associated from those of post-operative infections. White-Cell-Counts (WCC) and C-Reactive-Protein (CRP) are routinely used as markers for infection, but are non-specific and their elevation is often delayed in PM cases. Other markers need to be evaluated to assist early identification/prediction of post-operative infections.
METHODOLOGY: Prospective evaluation of serum procalcitonin (PCT), CRP and WCC in 50 patients pre-operatively (Day0), and on post-operative days (POD) 1, 3 & 6, following cytoreductive-surgery with or without splenectomy.
RESULTS: Day0 PCT, CRP and WCC values were within normal limits, but increasing physiologically in post-operative period without infection, with noticeable higher PCT in splenectomized patients. In our cohort post-operative infections were diagnosed in 14 patients, often within 48 h. There was a trend for faster rise in serum PCT on POD1 compared to CRP and WCC, and faster PCT decline following appropriate therapy on POD3 and POD6 when infected cases were clinically resolving while WCC and CRP continued to rise, particularly in non-spelenectomised patients. The AUC on POD1 was significantly higher for PCT (0.689) vs. WCC (0.476) and CRP (0.477) (p = 0.04). Sensitivity, specificity, positive-predictive-value and negative-predictive-values for PCT ranged between (57%-100%), (22%-74%), (33%-47%) & (81%-100%), for CRP (28%-78%), (5.5%-86%), (18%-44.4%) & (40%-75.5%) and for WCC (14%-26.5%), (65.5-80.5%), (22%-25%), (67%-70%) respectively.
CONCLUSION: PCT, like WCC and CRP, needs to be interpreted with extreme cautions in the context of infections post-cytoreductive-surgery and should only be used in association with other clinical and investigational findings.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytoreductive surgery; Peritoneal malignancy; Procalcitonin

Mesh:

Substances:

Year:  2015        PMID: 26560024     DOI: 10.1016/j.ejso.2015.10.004

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

Review 1.  Diagnostic accuracy of procalcitonin and interleukin-6 for postoperative infection in major gastrointestinal surgery: a systematic review and meta-analysis.

Authors:  E Jerome; M J McPhail; K Menon
Journal:  Ann R Coll Surg Engl       Date:  2022-09       Impact factor: 1.951

Review 2.  Biomarkers during COVID-19: Mechanisms of Change and Implications for Patient Outcomes.

Authors:  Cheng-Han Chen; Sheng-Wen Lin; Ching-Fen Shen; Kai-Sheng Hsieh; Chao-Min Cheng
Journal:  Diagnostics (Basel)       Date:  2022-02-16

Review 3.  Biomarkers for Evaluating the Inflammation Status in Patients with Cancer.

Authors:  Ali Guner; Hyoung-Il Kim
Journal:  J Gastric Cancer       Date:  2019-09-09       Impact factor: 3.720

4.  Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.

Authors:  Fang Liu; Lin Li; MengDa Xu; Juan Wu; Ding Luo; YuSi Zhu; BiXi Li; XiaoYang Song; Xiang Zhou
Journal:  J Clin Virol       Date:  2020-04-14       Impact factor: 3.168

5.  Early sepsis identification following cytoreductive surgery for peritoneal malignancy.

Authors:  Darius Cameron Wilson; Danylo Yershov; Chandrakumaran Kandiah; Nicholas Cortes; Kirsty Gordon; Kordo Saeed
Journal:  Crit Care       Date:  2020-03-23       Impact factor: 9.097

6.  Machine Learning Algorithms are Superior to Conventional Regression Models in Predicting Risk Stratification of COVID-19 Patients.

Authors:  Jiru Ye; Meng Hua; Feng Zhu
Journal:  Risk Manag Healthc Policy       Date:  2021-07-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.